close read more

OUR DEVELOPMENT PORTFOLIO

 

Updated April 2021
  • Oncology
  • Immune-inflammatory and neurodegenerative diseases
  • Cardiometabolism

Phase 1

Haematological malignancies

Mcl1 inhibitor

Haematological malignancies

Bcl2 inhibitor

Haematological malignancies

UCART 19

Haematological malignancies

Cart 19

Solid tumors

Anti PD1xAnti TIM3

Solid tumors

Anti CD73

Solid tumors

AG270

Relapsed or refractory myelodysplastic syndrome (MDS)

Tibsovo (pre-registration)

Phase 2

Colorectal cancer

Anti EGFR

Lung cancer

Anti cMET

Sjögren disease / Crohn's disease

Anti IL7R

Phase 3

Colorectal cancer, 1st line Combo

Lonsurf

Colorectal cancer, 3rd line Combo

Lonsurf

Autism

Bumetanide

Acute myeloid leukemia (AML) IC-ineligible, 1st line

Tibsovo

Acute myeloid leukemia (AML) IC-eligible, 1st line

Tibsovo

Cholangiocarcinoma

Tibsovo

Low-grade Glioma

Vorasidenib